Skip to main content

Automated Insulin Delivery System Improves Glycemic Control in Youth

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 12, 2024.

By Lori Solomon HealthDay Reporter

THURSDAY, Dec. 12, 2024 -- Initiation of an automated insulin delivery (AID) system improves glycemic control in children and adolescents with type 1 diabetes (T1D), according to a study published in the January issue of Diabetes, Obesity and Metabolism.

Maaria Kiilavuori, M.D., from the University of Helsinki, and colleagues investigated the influence of an AID system on glycemic control in children and adolescents with T1D who do not reach optimal glycemic control with traditional treatment options (hemoglobin A1C >53 mmol/mol/7.0 percent). The analysis included 79 patients (aged 7 to 16 years) with T1D.

The researchers found that after the initiation of an AID system, glycemic control improved and the effect persisted throughout the study period. Between zero and three months, time in tight range and time in range increased (mean, 11.7 and 18.1 percent, respectively). During the same follow-up period, hemoglobin A1c and mean sensor glucose values decreased significantly. These effects were sustained at 12 and 24 months.

"Glycemic control in patients not reaching treatment goals improved significantly after the initiation of the AID system, and the favorable effect lasted throughout the follow-up," the authors write. "AID treatment could be an option for also those pediatric patients with T1D who do not have good skills in diabetes management."

Several authors disclosed ties to the pharmaceutical and medical device industries.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Rise in Prevalence of Obesity in Youth, Adults With T1DM Seen From 2008 to 2023

FRIDAY, April 4, 2025 -- From 2008-2011 to 2020-2023, there was an increase in the prevalence of obesity among youth and adults with type 1 diabetes, and glucagon-like peptide 1...

Low-Glucose Alerts Beneficial for Insulin-Treated Drivers With Diabetes

FRIDAY, March 21, 2025 -- For individuals with type 1 diabetes, low-glucose alerts improve the time below range for drivers and reduce the incidence of low glucose while driving...

GLP-1 RA Use Tied to Better Kidney Transplant Outcomes in Patients With Diabetes

TUESDAY, March 18, 2025 -- Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with better graft and patient survival among kidney transplant recipients with...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.